Hillary Clinton accuses Canadian drugmaker Valeant of 'predatory pricing'

Hillary Clinton has stepped up her battle against predatory drug pricing in her bid to become the next U.S. president -- and she is setting her sights on Valeant Pharmaceuticals.

See Full Article

In a new campaign ad on her YouTube page, the front-runner for the Democratic presidential nomination vows to go after the Quebec-based drugmaker.

Valeant has been accused of gouging patients on drug costs -- allegations it has denied.

The ad posted Monday cites the case of a woman who has been taking a brand name medication since the 1980s that, at one time, it says cost about $180 for 10 shots.

The name of the medication is not disclosed in the ad, which appears to have been filmed at a town hall-type campaign stop in January.

The ad shows Clinton waving a letter and saying the cost of the woman's latest refill has shot up to $14,700 for the same 10 vials.

"The company is called Valeant Pharmaceuticals. I am going after them," Clinton tells the meeting to a round of applause.

"This is predatory pricing and we're going to make sure it is stopped."

Valeant said after it became aware of the patient's story in January, it contacted her to determine whether it could help cover the costs of the medication as part of a patient assistance program.

"She informed us that her insurance provider covers the drug, so it is not a significant out-of-pocket expenditure for her," Valeant said in a statement Tuesday.

Valeant also said there has been a generic version of the drug available since 2003 and that its share of the overall market for the medication has declined to less than one per cent.

"Whenever the sales volume of a drug declines, manufacturers must consider pricing adjustments to keep production of the drug viable," Valeant said. "Patients are able to choose generic versions of the drug, however, at significantly lower prices."

The company, one of several companies under investigation as the U.S. Congress looks at price increases for certain specialty drugs, has seen its share price plummet to well under $100 from above $346 last summer. On Tuesday, the stock fell $6.55 to settle at $87.94 on the Toronto Stock Exchange.



Advertisements

Latest Economic News

  • Payment systems modernization long overdue: BoC official

    Economic CTV News
    OTTAWA -- A senior Bank of Canada official says modernization of the country's core payments infrastructure is long overdue amid the rapid advance of new technologies -- and the risks that accompany them. In prepared remarks of a speech, deputy bank governor Sylvain Leduc says the system must be able to keep up with new payment options that, in recent years, have included innovations like PayPal, e-transfers and Apple Pay. Source
  • Feds release details of delayed methane reduction plan

    Economic CTV News
    CALGARY -- Companies in the energy sector would be required to regularly check equipment for leaks, make repairs, monitor emission levels and report them to Ottawa under the federal government's proposal to reduce methane emissions. Source
  • GM accused of installing 'defeat devices' in diesel trucks to beat emissions tests

    Economic CBC News
    A lawsuit on behalf of 705,000 GM Silverado and Sierra diesel truck owners alleges the vehicles have technology on them designed to beat emissions tests. (Rebecca Cook/Reuters) GM has been accused of installing "defeat devices" similar to the ones Volkswagen used in order to beat emissions tests on hundreds of thousands of diesel truck engines. Source
  • New Ford CEO shakes up management team

    Economic CTV News
    DETROIT -- Ford's new CEO is shaking up the company's senior management. The Dearborn, Michigan, automaker named a new head of global product development Thursday, as well as new heads of its operations in North America, Europe and Asia. Source
  • Indigenous activists want Dollarama to stop selling dreamcatchers beside Canada 150 items

    Economic CTV News
    Canadian discount retailer Dollarama is coming under fire by indigenous rights activists who are accusing the company of appropriating their culture by placing dreamcatchers alongside Canada 150 items on store shelves. An online petition created by grassroots indigenous activists in Stouffville, Ont. Source
  • Florida firm offers $807M to take over Canadian forest company Tembec

    Economic CBC News
    Montreal-based lumber, paper and pulp producer Tembec has received an $807 million US offer to take over the company from Florida-based conglomerate Rayonier Advanced Materials. Jacksonville-based Rayonier is offering Tembec shareholders $4.05 Cdn per share, or 0.2302 shares in the new combined company for every share that they own. Source
  • Marches to take place as Quebec construction strike enters Day 2

    Economic CTV News
    MONTREAL - Various marches will take place across Quebec in support of the province's construction strike as it enters Day 2. About 175,000 workers launched the unlimited general strike on Wednesday, crippling activity on major projects such as the Champlain Bridge and a Montreal superhospital. Source
  • Quebec construction strike: premier promises back-to-work legislation next week

    Economic CTV News
    MONTREAL -- Quebec Premier Philippe Couillard says he will begin the process of adopting back-to-work legislation on Monday if there is no agreement in the province's construction strike. Couillard told reporters in Jerusalem today he's giving the sides the weekend to hammer out a deal. Source
  • CIBC profit tops $1B last quarter

    Economic CBC News
    CIBC took in $3.7 billion in revenue during the period. (Nathan Denette/Canadian Press) CIBC had $1.05 billion of net income in its second quarter, up 11 per cent from a year ago when it reported $941 million of net income. Source
  • Royal Bank profit rises to $2.8B

    Economic CBC News
    Royal Bank of Canada has boosted its second-quarter net income by nine per cent to $2.81 billion. That compares with $2.57 billion during the second quarter of 2016. The profit amounted to $1.85 per share, compared with $1.66 per share during the same period last year. Source